Evidence types
Basic science articles covering early-stage IBD research, disease mechanisms, lab findings, microbiome work, genetics, and experimental models.
Page 9 of 15 · 709 articles
The study identifies a specific bacterial protein (OmpA) on probiotic-derived vesicles that reduced inflammation in a mouse colitis model by inhibiting TLR4/NF-κB signaling and improving barrier function, suggesting a...
This preclinical study suggests a plant-derived polysaccharide (THP) can repair the gut vascular barrier and reduce inflammation in experimental colitis via the S1P/S1PR2 pathway, pointing to a novel potential target for...
Early lab research suggests Aloe vera components may reduce intestinal inflammation and support mucus barrier repair in a zebrafish model, which could guide future IBD research on plant-derived therapies.
The study presents a novel nanomaterial approach that aims to protect both inflamed intestines and kidneys by restoring intestinal barrier function and microbiome balance—mechanisms relevant to IBD-related systemic...
Automated, annotation‑efficient lesion segmentation could speed image review and reduce labeling costs for Crohn’s disease imaging research and tool development. If robust, it may help create better AI tools to support...
This model could improve how researchers study IBD inflammation and early colorectal cancer in a human-derived, multicellular system that reproduces neuromuscular function and immune responses. That may speed preclinical...
The study presents a novel probiotic-based delivery system that targets both intestinal inflammation and anxiety/depression through the gut–brain axis, a potentially relevant concept for people with IBD who commonly...
The paper identifies a gut microbiome–driven pathway (flagellin → TLR5 → IL-15 → ARA) that might link intestinal microbial changes to systemic inflammation seen in long COVID and other immune-mediated diseases,...
These results highlight a new cellular mechanism (macrophage-driven ECM changes) that may protect enteric neurons during intestinal inflammation — a process linked to symptoms and complications in IBD.
The work links a specific post-transcriptional regulator (AUF1) to barrier dysfunction in UC and demonstrates that AUF1-restored organoids can enhance mucosal repair in mice, suggesting a possible new regenerative...
The report describes a novel small-molecule inhibitor (IMYX-3) targeting RAB27A to reduce neutrophil-mediated damage in ulcerative colitis models, which could point to a new therapeutic approach if later validated in...
This study describes a novel nanoparticle "nanomachine" approach aimed at fixing gut microbial and barrier dysfunction in IBD models and, by doing so, reducing secondary kidney injury—an intersection (gut–kidney axis)...
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.
The study proposes new biomarker candidates (C5AR1, KDM2A, HCAR3) and microbiota-derived metabolites that might interact with those targets. If validated, that could guide future diagnostic tests or microbiome-targeted...
Researchers are exploring new small molecules that might modulate T cells in IBD. This study found lab evidence of T‑cell inhibition for several compounds but no therapeutic benefit in a mouse colitis model, so these...
People with IBD may care because this study connects a genetic risk region to a molecular mechanism that restrains inflammation in T cells, offering a potential new biological clue about disease causes and future...
LRMDA may be a previously unrecognized protein important for mucus production and intestinal barrier integrity — processes directly relevant to IBD flares, infection risk, and colorectal cancer development. Understanding...
Quantitative, rapid stool tests could make it easier to track intestinal inflammation without central lab delays. If translated to clinical use, SERS-enhanced lateral-flow assays might allow more frequent, point-of-care...
The study suggests acetate (sodium acetate) can protect intestinal cells and reshape the gut microbiota in preclinical models of ulcerative colitis, pointing to a potential microbiome-linked therapeutic avenue that might...
This study suggests an environmental fungicide can disrupt gut microbes and reduce beneficial microbial tryptophan metabolites, promoting colitis in mice; dietary tryptophan reversed those effects in the model.
A new chemiluminescent probe may help researchers detect and visualize peroxynitrite, a reactive species linked to inflammation in ulcerative colitis, which could aid research into disease mechanisms and early detection...
The study introduces a phylogeny-aware AI method that may improve detection and interpretation of microbiome signatures linked to IBD and colorectal cancer, which could help research into microbial biomarkers relevant to...
The work suggests a new mechanism linking macrophage-driven ECM remodeling to protection of enteric neurons and reduced colitis in preclinical models, which could point to future therapies aimed at preventing neuronal...
The review outlines new research tools for investigating whether mycobacteria contribute to Crohn’s disease and how the microbiome might influence infection and intestinal inflammation, which could eventually inform...
The study suggests a specific microbial metabolite, 3‑HPA, can link cold exposure to worse colitis by changing the microbiome and harming epithelial cell mitochondria and barrier function — a possible new mechanistic...
The study links NEAT1, a long noncoding RNA, to neutrophil-driven mucosal inflammation in ulcerative colitis and suggests NEAT1 affects neutrophil activity via glycolysis. That points to a new molecular pathway that...
Anemia is a common complication of IBD and can worsen quality of life. This study suggests endotoxins leaking from an inflamed gut may drive anemia through TLR4 on tissue-resident macrophages, highlighting a possible new...
This work suggests a new way Crohn’s disease might begin: a weaker early immune response (linked to NOD2 gene defects) allows small intestinal infections to persist and later trigger the inflammation that causes...
The study describes a new ultrasound-activated nanozyme that reduced intestinal inflammation and promoted mucosal repair in preclinical IBD models by scavenging ROS and modulating the gut microbiota—an approach that...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Functional...
CAR-based cellular therapies could offer a new way to reset immune responses in some forms of IBD, potentially helping patients who do not respond to existing biologics or small molecules.
This study suggests a plant extract might boost ketone-body levels and reduce colitis-like inflammation in a mouse model — a concept that could inform future dietary or therapeutic research for ulcerative colitis but is...
This preclinical study suggests a fox-derived Lactiplantibacillus plantarum strain can reduce inflammation and improve intestinal barrier markers in cell and mouse models of colitis, which could inform future...
Preclinical research identified a plant-derived compound (polydatin) that may rebalance immune responses relevant to ulcerative colitis by targeting KEAP1–NFE2L2 signaling and reducing inflammatory T‑cell activity. This...
If validated, blood-based AI predictors of organ-specific aging might help flag organs aging faster in people with Crohn’s disease or other conditions, potentially enabling earlier monitoring or research into causes....
The paper reports a materials-based strategy to improve zinc delivery and bioavailability that reduced dose while preserving beneficial effects in a mouse colitis model—relevant because zinc supports intestinal health...
This preclinical study identifies Thymosin β4 as a protective factor in intestinal inflammation and fibrosis and suggests rhTβ4 could be explored as a new therapeutic approach for IBD by targeting mineralocorticoid...
The paper reports a novel small molecule (CA-23) that directly antagonizes CD28, reducing pathogenic T cell responses in preclinical IBD models and in cells from IBD donors. If validated, this represents a...
This research suggests a new, preclinical microbiome- and metabolite-based pathway (APA-1 → THDCA → TGR5/cAMP/PKA → NLRP3) that reduced inflammation in a mouse model of ulcerative colitis, which could guide future...
An organoid platform that models epithelial injury and recovery could help researchers test treatments and biomarkers more precisely and at scale, accelerating work relevant to Crohn’s disease and other IBDs.
The study suggests a new probiotic strategy that targets both microbial H2S production and host detoxification pathways — processes implicated in some IBD-related dysbiosis — which could inform future microbiome-directed...
This study links genetic risk variants to how intestinal epithelial cells respond and regenerate, which is directly relevant to IBD where barrier function and inflammation matter.
This study identifies FUT8, an enzyme that adds core fucose to N-glycans, as a possible new target to reduce pro-inflammatory T-cell responses in IBD. For people with IBD, new mechanisms in preclinical research may...
This study explores a potential mechanism linking a MAP infection model to inflammatory and metabolic pathways relevant to Crohn’s disease and tests whether methylglyoxal can lessen inflammatory programming in...
This study reports early-stage lab and mouse evidence for new small molecules that target the JAK2–STAT3 immune signaling pathway, a pathway relevant to inflammation in ulcerative colitis. If findings are confirmed in...
The study describes a microbiota-responsive cytotoxic CD4+ T‑cell state that associates with worse mucosal inflammation and reduced response to common biologic therapies in ulcerative colitis, suggesting a possible...
This work explores a novel, programmable way to deliver anti-inflammatory protein therapy (IL-10) directly in the gut using engineered yeast and wearable electronics. If further developed and translated, it could offer a...
This paper offers a multi-layered ecological perspective on UC-associated microbiome changes that could help researchers identify which microbial functions or taxa are driven more by random processes versus selection in...
